| Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface IJ De Vries-van Leeuwen, D da Costa Pereira, KD Flach, SR Piersma, ... Proceedings of the National Academy of Sciences 110 (22), 8894-8899, 2013 | 137 | 2013 |
| MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1 K Azijli, S Yuvaraj, I van Roosmalen, K Flach, E Giovannetti, GJ Peters, ... Apoptosis 18, 851-860, 2013 | 47 | 2013 |
| PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance R De Leeuw, K Flach, C Bentin Toaldo, X Alexi, S Canisius, J Neefjes, ... Oncogene 32 (30), 3543-3551, 2013 | 47 | 2013 |
| Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells CF Lai, KD Flach, X Alexi, SP Fox, S Ottaviani, PTR Thiruchelvam, FJ Kyle, ... Nucleic acids research 41 (22), 10228-10240, 2013 | 46 | 2013 |
| Comparative cistromics reveals genomic cross-talk between FOXA1 and ERα in tamoxifen-associated endometrial carcinomas M Droog, E Nevedomskaya, Y Kim, T Severson, KD Flach, M Opdam, ... Cancer research 76 (13), 3773-3784, 2016 | 29 | 2016 |
| SRC3 phosphorylation at serine 543 is a positive independent prognostic factor in ER-positive breast cancer W Zwart, KD Flach, B Rudraraju, TMA Abdel-Fatah, O Gojis, S Canisius, ... Clinical Cancer Research 22 (2), 479-491, 2016 | 24 | 2016 |
| Endonuclease FEN1 Coregulates ERα activity and provides a novel drug Interface in Tamoxifen-resistant breast Cancer KD Flach, M Periyasamy, A Jadhav, D Dorjsuren, JC Siefert, TE Hickey, ... Cancer research 80 (10), 1914-1926, 2020 | 22 | 2020 |
| A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation G Korkmaz, Z Manber, R Lopes, S Prekovic, K Schuurman, Y Kim, ... Nucleic Acids Research 47 (18), 9557-9572, 2019 | 22 | 2019 |
| The first decade of estrogen receptor cistromics in breast cancer KD Flach, W Zwart J Endocrinol 229 (2), R43-R56, 2016 | 19 | 2016 |
| A Mediator-cohesin axis controls heterochromatin domain formation JHI Haarhuis, RH van der Weide, VA Blomen, KD Flach, H Teunissen, ... Nature Communications 13 (1), 754, 2022 | 17 | 2022 |
| Distinct roles for CKM–Mediator in controlling Polycomb-dependent chromosomal interactions and priming genes for induction E Dimitrova, A Feldmann, RH van der Weide, KD Flach, A Lastuvkova, ... Nature structural & molecular biology 29 (10), 1000-1010, 2022 | 11 | 2022 |
| Perturbations in 3D genome organization can promote acquired drug resistance AG Manjón, SG Manzo, S Prekovic, L Potgeter, T van Schaik, NQ Liu, ... Cell Reports 42 (10), 2023 | 7 | 2023 |
| Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational … Z Szijgyarto, KD Flach, M Opdam, C Palmieri, SC Linn, J Wesseling, S Ali, ... Breast Cancer Research and Treatment 175, 149-163, 2019 | 5 | 2019 |
| A CRISPR-Cas9 screen identifies essential CTCF anchor sites for the mitogenic function of ER-alpha in breast cancer G Korkmaz, Z Manber, R Marques Lopes, S Prekovic, K Schuurman, ... Nucleic Acids Research, 2019 | | 2019 |
| Holding the balance; the equilibrium between ERα-activation, epigenetic alterations and chromatin integrity KD Flach Leiden University, 2018 | | 2018 |
| Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ER alpha in Tamoxifen-Associated Endometrial Carcinomas (vol 76, pg 3773, 2016) M Droog, E Nevedomskaya, Y Kim, T Severson, KD Flach, M Opdam CANCER RESEARCH 78 (9), 2446-2446, 2018 | | 2018 |
| Estrogen receptor cistromics in breast tumors: from biomarkers to novel drug targets KD Flach, M Periyasamy, A Jadhav, TE Hickey, M Opdam, H Patel, ... Endocrine Abstracts 54, 2018 | | 2018 |
| NAR Breakthrough Article: Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells CF Lai, KD Flach, X Alexi, SP Fox, S Ottaviani, PTR Thiruchelvam, FJ Kyle, ... Nucleic Acids Research 41 (22), 10228, 2013 | | 2013 |
| Holding the balance; the equilibrium between ERα-activation, epigenetic KD Flach cancer 30 (23), 4764-76, 2011 | | 2011 |
| FEN1-IN-4 KD Flach, M Periyasamy, A Jadhav, D Dorjsuren, JC Siefert, TE Hickey, ... | | |
